Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

B. Vellas; M.C. Carrillo; C. Sampaio; H.R. Brashear; E. Siemers; H. Hampel; L.S. Schneider; M. Weiner; R. Doody; Z. Khachaturian; J. Cedarbaum; M. Grundman; K. Broich; E. Giacobini; B Dubois; R. Sperling; G.K. Wilcock; N.C. Fox; P. Scheltens; J. Touchon; S. Hendrix; S. Andrieu; P. Aisen

doi:10.1016/j.jalz.2013.03.007

Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

B. Vellas, M.C. Carrillo, C. Sampaio, H.R. Brashear, E. Siemers, H. Hampel, L.S. Schneider, M. Weiner, R. Doody, Z. Khachaturian, J. Cedarbaum, M. Grundman, K. Broich, E. Giacobini, B Dubois, R. Sperling, G.K. Wilcock, N.C. Fox, P. Scheltens, J. TouchonS. Hendrix, S. Andrieu, P. Aisen

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	438-444
Journal	Alzheimers & Dementia
Volume	9
Issue number	4
DOIs	https://doi.org/10.1016/j.jalz.2013.03.007
Publication status	Published - 2013

Access to Document

10.1016/j.jalz.2013.03.007

Cite this

Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., ... Aisen, P. (2013). Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. Alzheimers & Dementia, 9(4), 438-444. https://doi.org/10.1016/j.jalz.2013.03.007

Vellas, B. ; Carrillo, M.C. ; Sampaio, C. ; Brashear, H.R. ; Siemers, E. ; Hampel, H. ; Schneider, L.S. ; Weiner, M. ; Doody, R. ; Khachaturian, Z. ; Cedarbaum, J. ; Grundman, M. ; Broich, K. ; Giacobini, E. ; Dubois, B ; Sperling, R. ; Wilcock, G.K. ; Fox, N.C. ; Scheltens, P. ; Touchon, J. ; Hendrix, S. ; Andrieu, S. ; Aisen, P. / Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. In: Alzheimers & Dementia. 2013 ; Vol. 9, No. 4. pp. 438-444.

@article{79620cbd81b04e31a3c867b74b609f8a,

title = "Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force",

author = "B. Vellas and M.C. Carrillo and C. Sampaio and H.R. Brashear and E. Siemers and H. Hampel and L.S. Schneider and M. Weiner and R. Doody and Z. Khachaturian and J. Cedarbaum and M. Grundman and K. Broich and E. Giacobini and B Dubois and R. Sperling and G.K. Wilcock and N.C. Fox and P. Scheltens and J. Touchon and S. Hendrix and S. Andrieu and P. Aisen",

year = "2013",

doi = "10.1016/j.jalz.2013.03.007",

language = "Undefined/Unknown",

volume = "9",

pages = "438--444",

journal = "Alzheimers & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "4",

}

Vellas, B, Carrillo, MC, Sampaio, C, Brashear, HR, Siemers, E, Hampel, H, Schneider, LS, Weiner, M, Doody, R, Khachaturian, Z, Cedarbaum, J, Grundman, M, Broich, K, Giacobini, E, Dubois, B, Sperling, R, Wilcock, GK, Fox, NC, Scheltens, P, Touchon, J, Hendrix, S, Andrieu, S & Aisen, P 2013, 'Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force', Alzheimers & Dementia, vol. 9, no. 4, pp. 438-444. https://doi.org/10.1016/j.jalz.2013.03.007

Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. / Vellas, B.; Carrillo, M.C.; Sampaio, C.; Brashear, H.R.; Siemers, E.; Hampel, H.; Schneider, L.S.; Weiner, M.; Doody, R.; Khachaturian, Z.; Cedarbaum, J.; Grundman, M.; Broich, K.; Giacobini, E.; Dubois, B; Sperling, R.; Wilcock, G.K.; Fox, N.C.; Scheltens, P.; Touchon, J.; Hendrix, S.; Andrieu, S.; Aisen, P.

In: Alzheimers & Dementia, Vol. 9, No. 4, 2013, p. 438-444.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force

AU - Vellas, B.

AU - Carrillo, M.C.

AU - Sampaio, C.

AU - Brashear, H.R.

AU - Siemers, E.

AU - Hampel, H.

AU - Schneider, L.S.

AU - Weiner, M.

AU - Doody, R.

AU - Khachaturian, Z.

AU - Cedarbaum, J.

AU - Grundman, M.

AU - Broich, K.

AU - Giacobini, E.

AU - Dubois, B

AU - Sperling, R.

AU - Wilcock, G.K.

AU - Fox, N.C.

AU - Scheltens, P.

AU - Touchon, J.

AU - Hendrix, S.

AU - Andrieu, S.

AU - Aisen, P.

PY - 2013

Y1 - 2013

U2 - 10.1016/j.jalz.2013.03.007

DO - 10.1016/j.jalz.2013.03.007

M3 - Article

VL - 9

SP - 438

EP - 444

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

IS - 4

ER -